Plain-English translation of NCT07553780 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether repeated PSMA PET scans — a special type of imaging that detects prostate cancer cells very accurately — can help doctors monitor how well your treatment is working. Researchers want to understand if these scans taken at different times during and after treatment can predict your long-term health outcomes and guide future care decisions.
Doctors currently use blood tests and standard imaging to check if prostate cancer treatment is working, but these tools aren't always reliable. This study exists to see if this new imaging approach can give doctors better, earlier information about treatment success and help them make smarter decisions about your ongoing care.
You likely qualify if…
You likely don't qualify if…
You will have a baseline imaging scan before starting any treatment, followed by a second scan either when blood tests show signs of cancer recurrence or at 12–24 months after your treatment ends (whichever comes first). Both scans use the same type of radioactive dye and imaging machine to track changes in your cancer. The study team will use these images along with your regular clinical care to understand how well treatment is working.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhua Jiao, MD.
Xijing Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.